Ranilair 50 Injection contains Ranitidine 50 mg per 2 ml, a histamine H2-receptor antagonist that reduces the amount of acid produced in the stomach. It is primarily used in clinical settings for the treatment and prevention of ulcers in the stomach and intestines, and to relieve symptoms of gastroesophageal reflux disease (GERD) and hyperacidity conditions, including Zollinger-Ellison syndrome.
This injection form is particularly useful when oral administration is not feasible — for instance, in patients who are unconscious, vomiting, or undergoing surgery. Ranitidine works by blocking histamine H2 receptors on the stomach lining, thereby decreasing gastric acid secretion. This helps in healing ulcers, alleviating acid reflux symptoms, and preventing acid-induced damage during critical illnesses.
Ranilair 50 is widely used in pre-operative care to reduce gastric acid volume and acidity, minimizing the risk of aspiration pneumonia. It also aids in the management of stress ulcers in critically ill patients, particularly in intensive care units.
While ranitidine has a well-established role in acid suppression therapy, its use has come under regulatory scrutiny due to concerns related to impurities in some formulations. Always ensure it is used from a verified, quality-assured source and under proper medical supervision.